Skip to main content
POOLBEG PHARMA PLC logo

POOLBEG PHARMA PLC — Investor Relations & Filings

Ticker · POLB ISIN · GB00BKPG7Z60 LEI · 213800UZ8WJLWYHBFL52 IL Manufacturing
Open in API
Filings indexed 160 across all filing types
Latest filing 2026-04-28 Annual Report
Country GB United Kingdom
Listing IL POLB

About POOLBEG PHARMA PLC

https://poolbegpharma.com/

Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company that develops and commercializes medicines for diseases with high unmet medical needs. The company's lead asset, POLB 001, is a treatment designed to prevent Cytokine Release Syndrome (CRS), a severe side effect associated with cancer immunotherapies, with the aim of making these treatments safer and more accessible. Poolbeg is also advancing an oral GLP-1 program for obesity, offering a patient-friendly therapeutic option. The company utilizes an artificial intelligence (AI)-led discovery platform that analyzes data from human challenge trials to identify novel drug targets. This AI-driven approach aims to accelerate target identification, reduce costs, and lower development risks.

Recent filings

Filing Released Lang Actions
Results for the year ended 31 December 2025
Annual Report Classification · 1% confidence The document is an RNS regulatory announcement titled “Results for the year ended 31 December 2025” and includes audited full‐year results, detailed narrative statements by the CEO and Executive Chair, highlights of operational and financial performance, pipeline updates, patented grants, and the beginning of the annual report and financial statements. The length (~48,000 characters) and depth (including Chair’s statement, financial positions, operational review) indicate this is the full annual report rather than a brief earnings release or preview announcement. Therefore, it should be classified as an Annual Report (10-K). FY 2025
2026-04-28 English
Significant milestone for Poolbeg's IP portfolio
Regulatory Filings Classification · 1% confidence The document is an RNS announcement from Poolbeg Pharma plc regarding the grant of a patent by IP Australia. It is not a financial report, earnings release, AGM material, management change, or share transaction. It does not attach a full report, nor does it fit any specific category like M&A, dividends, or director dealings. Therefore it falls under a general regulatory announcement category (RNS).
2026-03-31 English
Appointment of Dr Adrian Kilcoyne to SAB
Regulatory Filings Classification · 1% confidence The document is a press release announcing the appointment of a new member to the Scientific Advisory Board of Poolbeg Pharma. This falls under the category of management or board-level personnel changes. While it is distributed via RNS, it is a substantive announcement of a corporate appointment rather than a mere report publication notice or a general regulatory filing.
2026-03-12 English
Notification of Major Holdings
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in share ownership (from 5.03% to 6.14%) by a shareholder (Michael Kelly) in Poolbeg Pharma PLC. This matches the definition for 'Major Shareholding Notification' (MRQ), which covers notifications of changes in significant share ownership levels crossing regulatory thresholds.
2026-02-09 English
POLB 001 LPS Challenge Trial Paper Published
Regulatory Filings Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from Poolbeg Pharma PLC regarding the publication of a peer-reviewed clinical trial paper in 'Frontiers in Immunology'. It provides a summary of the trial results and their implications for the company's drug development. Since it is a general regulatory announcement that does not fit into specific categories like financial reports, earnings releases, or board changes, it falls under the 'Regulatory Filings' (RNS) category.
2026-01-28 English
Exercise of Options & Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement from Poolbeg Pharma PLC regarding the issuance and allotment of new ordinary shares following the exercise of employee options. It also includes a 'Total Voting Rights' disclosure, which is a standard regulatory requirement in the UK when share capital changes. This falls under the category of 'Share Issue/Capital Change' (SHA) as it details the creation of new shares and the resulting change in total voting rights.
2026-01-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.